Download  full announcement  Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital of the Company

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it is participating in a London based event focused on Kidney Health that will bring together senior officials from leading health

Download  full announ c ement Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians’ Health Plan,

Download  full  announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.

Download  full announ c ement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that CPT reimbursement code 0105U for its  KidneyIntelX™  test has become effective nationally in the United States as of October 1, 2019. 

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising

Download  full announement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Centers for Medicare & Medicaid Services (“CMS”) has published its preliminary determination for national Medicare pricing for the

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical  in vitro  diagnostics for kidney disease, confirms that the Annual Report and Accounts for the period ended 30 June 2019  (“2019 Annual Report”), the Notice of the Annual General

Download  full announcement Renalytix AI plc (AIM: RENX), the AIM listed developer of artificial intelligence-enabled diagnostics for kidney disease, announces its inaugural final results for the period ended June 30, 2019. Operational highlights The U.S.